Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD44 | P16070 | 2/20 | 0.49 |
| ▸ | TRPA1 | O75762 | 4/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | PNMT | P11086 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CFTR | P13569 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29609011 | 1.00 | CD44 (0.49) | CD44TRPA1CHRM3LMNATSHR | |
| Hydrochloric Acid SCHEMBL4438179 | 0.98 | CD44 (0.47) | CD44TRPA1CHRM3LMNATSHR | |
| SCHEMBL29801456 | 0.88 | PNMT (0.49) | TRPA1LMNATSHRPNMT | |
| SCHEMBL567532 | 0.88 | PNMT (0.49) | TRPA1LMNATSHRPNMT | |
| Hydrochloric Acid SCHEMBL4158562 | 0.87 | PNMT (0.47) | TRPA1LMNATSHRPNMT | |
| Hydrochloric Acid SCHEMBL30319882 | 0.87 | PNMT (0.47) | TRPA1LMNATSHRPNMT | |
| SCHEMBL6095089 | 0.86 | TRPA1 (0.48) | TRPA1CHRM3LMNATSHRALDH1A1 | |
| Hydrochloric Acid SCHEMBL29877364 | 0.84 | TRPA1 (0.47) | TRPA1CHRM3LMNATSHRALDH1A1 | |
| Hydrochloric Acid SCHEMBL6093232 | 0.84 | TRPA1 (0.47) | TRPA1CHRM3LMNATSHRALDH1A1 | |
| SCHEMBL20944698 | 0.84 | TSHR (0.50) | CD44TSHRALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010022055-A2 | INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | AMGEN INC. (US) | 2010-02-25 | — | — | WO | claimed |
| CN-115073474-A | Pyrrolo [2,3-b ] pyrazines as HPK1 inhibitors and uses thereof | 百济神州有限公司 | 2022-09-20 | — | — | CN | disclosed |
| CN-115028639-A | Pyrrolo [2,3-b ] pyrazines as HPK1 inhibitors and uses thereof | 百济神州有限公司 | 2022-09-09 | — | — | CN | disclosed |
| CN-114096536-A | Pyrrolo [2,3-b ] pyrazines as HPK1 inhibitors and uses thereof | 百济神州有限公司 | 2022-02-25 | — | — | CN | disclosed |
| CN-108602811-B | FXR receptor agonists | 轩竹生物科技有限公司 | 2021-11-16 | — | — | CN | disclosed |
| EP-3194367-B1 | TETRAHYDROISOQUINOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR THE TREATMENT OF OBESITY AND DIABETES | BOEHRINGER INGELHEIM INT (DE) | 2021-08-18 | — | — | EP | disclosed |
| EP-3194367-B1 | TETRAHYDROISOQUINOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR THE TREATMENT OF OBESITY AND DIABETES | BOEHRINGER INGELHEIM INT (DE) | 2021-08-18 | — | — | EP | disclosed |
| CN-108602811-A | FXR receptor stimulating agents | 山东轩竹医药科技有限公司 | 2018-09-28 | — | — | CN | disclosed |
| WO-2017133521-A1 | FXR RECEPTOR AGONIST | 山东轩竹医药科技有限公司 | 2017-08-10 | — | — | WO | disclosed |
| CN-107001278-A | Tetrahydro isoquinoline derivative | UCB生物制药私人有限公司 | 2017-08-01 | — | — | CN | disclosed |
| US-8338455-B2 | Pyridines or pyrimidines having 4-(hydrogenated 1-pyridyl- or hydrogenated 1-isoquinolyl rings, e.g., N-(4-chlorophenyl)-2-(pyridin-4-ylmethyl)-1,2,3,4-tetrahydroisoquinoline-5-carboxamide; kinase inhibitors; inflammation, angiogenesis and cancer | AMGEN INC. (US) | 2012-12-25 | — | — | US | disclosed |
| EP-2118088-B1 | Heterocyclic compounds and their use in treating inflammation, angiogenesis and cancer | AMGEN INC (US) | 2012-05-30 | — | — | EP | disclosed |
| WO-2011103196-A1 | ARYL CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS FOR TREATMENT OF PAIN | AMGEN INC. (US) | 2011-08-25 | — | — | WO | disclosed |
| US-20100173899-A1 | DIPEPTIDE ANALOGS AS COAGULATION FACTOR INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-07-08 | — | — | US | disclosed |
| WO-2010022055-A2 | INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | AMGEN INC. (US) | 2010-02-25 | — | — | WO | disclosed |
| EP-2152664-A1 | DIPEPTIDE ANALOGS AS COAGULATION FACTOR INHIBITORS | Brystol-Myers Squibb Company (US) | 2010-02-17 | — | — | EP | disclosed |
| WO-2008157162-A1 | DIPEPTIDE ANALOGS AS COAGULATION FACTOR INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-24 | — | — | WO | disclosed |
| US-20080161346-A1 | Compounds and methods of use | AMGEN INC. (US) | 2008-07-03 | — | — | US | disclosed |
| US-20080161346-A1 | Compounds and methods of use | AMGEN INC. (US) | 2008-07-03 | — | — | US | disclosed |
| WO-2008079292-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE IN TREATING INFLAMMATION, ANGIOGENESIS AND CANCER | AMGEN INC. (US) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161346-A1 | Compounds and methods of use | VHL, VEGFA, FLT1 | CD44 698/4885TRPA1 3965/4885CHRM3 3400/4885 |
| US-20100173899-A1 | DIPEPTIDE ANALOGS AS COAGULATION FACTOR INHIBITORS | F11, TFPI, SERPINC1 | CD44 4314/4885TRPA1 4723/4885CHRM3 4792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.